Can AMRX sustain its EPS growth trend?

**Amneal Pharmaceuticals (AMRX) faces challenges in sustaining its EPS growth trend.** Here's why:

1. **Recent Performance**: In Q4 2024, AMRX missed EPS expectations, with an EPS of $0.12, falling short of the anticipated $0.15. This marks a departure from the company's previous performance, raising questions about its ability to maintain consistent EPS growth.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|AMRX|AMRX.O|Amneal|2024 Q1|-500|-0.3|185|
|AMRX|AMRX.O|Amneal|2024 Q2|-75|0.02|185|

|code|Ticker|Name|Date|P/E(TTM)|market_code|
|---|---|---|---|---|---|
|AMRX|AMRX.O|Amneal|20240415|-10.135402|185|
|AMRX|AMRX.O|Amneal|20240416|-9.970747|185|
|AMRX|AMRX.O|Amneal|20240417|-9.989042|185|
|AMRX|AMRX.O|Amneal|20240418|-9.806093|185|
|AMRX|AMRX.O|Amneal|20240419|-9.915862|185|
|AMRX|AMRX.O|Amneal|20240422|-9.824388|185|
|AMRX|AMRX.O|Amneal|20240423|-9.879272|185|
|AMRX|AMRX.O|Amneal|20240424|-11.068444|185|
|AMRX|AMRX.O|Amneal|20240425|-10.79402|185|
|AMRX|AMRX.O|Amneal|20240426|-10.739135|185|

2. **Financial Metrics**: The company's Free Cash Flow stands at $93.91 million, with Operating Cash Flow at $118.08 million and Financing Cash Flow at -$61.2 million. While the positive Free Cash Flow is a sign of good financial health, the negative Financing Cash Flow suggests ongoing financial adjustments that could impact future EPS stability.

|code|Ticker|Name|Date|Free Cash Flow|Investing Cash Flow|Operating Cash Flow|Financing Cash Flow|market_code|
|---|---|---|---|---|---|---|---|---|
|AMRX|AMRX.O|Amneal|2024 Q1|2.8730623853E7|-1.976E7|-4410000|-2.3155E7|185|
|AMRX|AMRX.O|Amneal|2024 Q2|3.3409531826E8|-6465000|3.9657E7|-3.5086E7|185|
|AMRX|AMRX.O|Amneal|2024 Q3|6.0977155301E8|-2.0712E7|1.41774E8|-9.2346E7|185|
|AMRX|AMRX.O|Amneal|2024 Q4|5.36917806906E8|-1.6059E7|1.18078E8|-6.1204E7|185|

3. **Market Expectations**: Analysts anticipate a year-over-year decline in earnings on higher revenues for the quarter ending June 2024. This expectation of earnings decline suggests that AMRX may not be on track to sustain its EPS growth trend.
4. **Historical Trends**: The EPS Stability Indicator shows a significant drop, with a -20% percentage of EPS surprise. This indicates that the company's EPS has not been stable and may continue to face challenges in sustaining growth.

|code|Ticker|Name|Date|Estimate EPS YoY|Estimate EPS|market_code|
|---|---|---|---|---|---|---|
|AMRX|AMRX.O|Amneal|20240331|-10.000000000000009|0.09|185|
|AMRX|AMRX.O|Amneal|20240630|40.00000000000001|0.14|185|
|AMRX|AMRX.O|Amneal|20240930|0|0.13|185|
|AMRX|AMRX.O|Amneal|20241231|66.66666666666666|0.15|185|

In conclusion, while AMRX has demonstrated resilience in the past, the recent miss on EPS expectations, combined with negative Financing Cash Flow and anticipated earnings decline, suggests that sustaining EPS growth may be challenging for the company.